摘要
目的观察EP与TP方案同步化放疗治疗Ⅲ期非小细胞肺癌的疗效。方法86例Ⅲ期非小细胞肺癌患者随机分为TP组42例和EP组44例,EP组采用EP方案化疗4个周期,TP组采用TP方案化疗4个周期,并于第1周期化疗第1天开始放疗。两组放射治疗均采用6MVX直线加速器常规分割治疗,放射治疗总量DT60~70Gy,6~7周完成。结果EP组CR8例,PR30例,有效率(CR+PR)86.4%;TP组CR8例,PR29例,有效率(CR+PR)88.1%,两组有效率差异无统计学意义(P>0.05)。EP组1、2、3年生存率分别为65.9%、45.5%、29.5%;TP组和EP组中位生存期分别为19.2个月和l8.5个月。2组间中位生存期及1、2、3年生存率差异无统计学意义(P>0.05)。两组的恶心、呕吐、骨髓抑制、放射性食管炎和放射性肺炎发生差异无统计学意义(P>0.05)。结论EP与TP方案同步化放疗均能对Ⅲ期NSCLC起到很好的疗效,TP组在近期有效率、中位生存期及2、3年生存期上均较EP组高;而EP组的不良反应发生率较低,患者的生活质量和治疗依从性相对较好。
Objective To evaluate the effects of concurrent chemoradiotherapy with EP and TP Regimens in stage Ⅲ non-small-cell lung cancer(NSCLC).Methods From February 2002 to October 2006,86 patients with stage Ⅲ NSCLC were randomized into two groups:TP group(42 patients) received radiotherapy plus concurrent chemotherapy with Paclitaxel(150mg/m^2,d1) and DDP(25mg/m^2,d1-d3) per cycle for 4 cycles.EP group(44 patients) received radiotherapy plus concurrent chemotherapy with DDP(25mg/m^2,d1-d3) and Vp-16(100 mg/m^2,d1-d3) per cycle for 4 cycles.In both groups,radiation was given to a total dose of 60-70Gy/6-7 weeks.Results The overall response rate(CR+PR) in EP group was 86.4% with a complete response(CR) rate of 18.2%.The overall response rate in TP group was 88.1% with a CR rate of 19.1%.The median survival periods were 19.2 months in TP group and 18.5 months in EP group(P0.05).The l-,2-and 3-year survival rates were 64.3%,47.6%,33.3%,and 65.9%,45.5%,29.5% in TP and EP groups,and the difference in the survival rates was no significant(P0.05).Conclusion There is no significant survival advantage for cisplatin-paclitaxel compared with cisplatin-etoposide.Concurrent chemoradiation with EP and TP regimens in stage Ⅲ non-small-cell lung cancer patients is acceptable.
出处
《医药论坛杂志》
2010年第3期7-9,共3页
Journal of Medical Forum
关键词
肺肿瘤
非小细胞肺癌
放射疗法
化学疗法
紫杉醇
足叶乙甙
顺铂
Lung neoplasms Non-small cell lung cancer Radiotherapy Chemotherapy Etoposide Cisplatin Paclitaxel